Drugs / Ad5.hAC6
last change Jun 2023 re-read 3 minutes ago

Ad5.hAC6

Developed for
congestive heart failure · heart failure
Investigated by
Renova Therapeutics · Hammond, H. Kirk, M.D. · National Heart, Lung, and Blood Institute (NHLBI)

Trials 2

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT00787059 Jul 2010 → Jan 2015 congestive heart failure Hammond, H. Kirk, M.D. Completed No outcome recorded
Phase 31 trial
Phase 3 NCT03360448 Jun 2019 → Jun 2020 heart failure Renova Therapeutics Withdrawn No outcome recorded Stop: Business

News releases announcing trial results or a regulatory action · 2

DateIssuerRelease
2017-04-11 Renova Therapeutics Results ‘Human Gene Therapy’ publishes review of randomized clinical trials of gene transfer for heart failure with reduced ejection fraction renovatherapeutics.com ↗
The review finds that, while efficacy varied among the clinical trials, gene transfer was not associated with an increased rate of adverse events, supporting further investigations using this treatment method in the HFrEF patient population.
2016-03-30 Renova Therapeutics Results JAMA Cardiology publishes Phase 2 results of AC6 gene transfer in patients with heart failure renovatherapeutics.com ↗
Results indicate that, through a one-time administration, AC6 gene transfer safely increased heart function beyond optimal heart failure therapy.

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Ad5.hAC6 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03360448 ↗
1

NCT00787059 ↗